|
1
|
Ford DR, Wilson D, Sothi S, Grimer R and
Spooner D: Primary bone lymphoma - treatment and outcome. Clin
Oncol (R Coll Radiol). 19:50–55. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ramadan KM, Shenkier T, Sehn LH, Gascoyne
RD and Connors JM: A clinicopathological retrospective study of 131
patients with primary bone lymphoma: a population-based study of
successively treated cohorts from the British Columbia Cancer
Agency. Ann Oncol. 18:129–135. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Krishnan A, Shirkhoda A, Tehranzadeh J, et
al: Primary bone lymphoma: Radiographic-MR imaging correlation.
Radiographics. 23:1371–1387; discussion 1384–1387. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mengiardi B, Honegger H, Hodler J, et al:
Primary lymphoma of bone: MRI and CT characteristics during and
after successful treatment. Am J Roentgenol. 184:185–192. 2005.
View Article : Google Scholar
|
|
5
|
Glotzbecker MP, Kersun LS, Choi JK, et al:
Primary non-Hodgkin's lymphoma of bone in children. J Bone Joint
Surg Am. 88:583–594. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lister TA, Crowther D, Sutcliffe SB, et
al: Report of a committee convened to discuss the evaluation and
staging of patients with Hodgkin's disease: Cotswolds meeting. J
Clin Oncol. 7:1630–1636. 1989.PubMed/NCBI
|
|
7
|
Reddy N and Greer JP: Primary bone
lymphoma: A set of unique problems in management. Leuk Lymphoma.
51:1–2. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhao XF, Young KH, Frank D, et al:
Pediatric primary bone lymphoma - diffuse large B-cell lymphoma:
Morphologic and immunohistochemical characteristics of 10 cases. Am
J Clin Pathol. 127:47–54. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bruno Ventre M, Ferreri AJ, Gospodarowicz
M, et al: International Extranodal Lymphoma Study Group: Clinical
features, management, and prognosis of an international series of
161 patients with limited-stage diffuse large B-cell lymphoma of
the bone (the IELSG-14 study). Oncologist. 19:291–298. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Beal K, Allen L and Yahalom J: Primary
bone lymphoma: treatment results and prognostic factors with
long-term follow-up of 82 patients. Cancer. 106:2652–2656. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
No authors listed: A predictive model for
aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's
Lymphoma Prognostic Factors Project. N Engl J Med. 329:987–994.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cheson BD, Horning SJ, Coiffier B, et al:
Report of an international workshop to standardize response
criteria for non-Hodgkin's lymphoma. NCI Sponsored International
Working Group. J Clin Oncol. 17:12441999.PubMed/NCBI
|
|
13
|
Langley CR, Garrett SJ, Urand J, Kohler J
and Clarke NM: Primary multifocal osseous Hodgkin's lymphoma. World
J Surg Oncol. 6:342008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gupta A, Kataria SP, Kumar K and
Subramanian S: Primary non Hodgkin's lymphoma of sternum. Indian J
Med Paediatr Oncol. 27:282006.
|
|
15
|
Levitt LJ, Aisenberg AC, Harris NL, et al:
Primary non-Hodgkin's lymphoma of the mediastinum. Cancer.
50:2486–2492. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kabiri el H, Kabiri M and Doghmi K:
Primary non-Hodgkin lymphoma of the sternum. Arch Bronconeumol.
45:259–260. 2009.(In Spanish). View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Maslovsky I and Gefel D: Hodgkin's
disease. Haematologica. 90 (12 Suppl):EIM022005.PubMed/NCBI
|
|
18
|
Graziadio M, Medina N, Amato M, et al:
Primary bone lymphoma with multicentric involvement. Medicina (B
Aires). 72:4284302012.(In Spanish). PubMed/NCBI
|
|
19
|
Heyning FH, Hogendoorn PC, Kramer MH, et
al: Primary non-Hodgkin's lymphoma of bone: a clinicopathological
investigation of 60 cases. Leukemia. 13:2094–2098. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Demircay E, Hornicek FJ Jr, Mankin HJ and
Degroot H III: Malignant lymphoma of bone: a review of 119
patients. Clin Orthop Relat Res. 471:2684–2690. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dubey P, Ha CS, Besa PC, et al: Localized
primary malignant lymphoma of bone. Int J Radiat Oncol Biol Phys.
37:1087–1093. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mikhaeel NG: Primary bone lymphoma. Clin
Oncol (R Coll Radiol). 24:366–370. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Moog F, Kotzerke J and Reske SN: FDG PET
can replace bone scintigraphy in primary staging of malignant
lymphoma. J Nucl Med. 40:1407–1413. 1999.PubMed/NCBI
|
|
24
|
Park YH, Kim S, Choi SJ, et al: Clinical
impact of whole-body FDG-PET for evaluation of response and
therapeutic decision-making of primary lymphoma of bone. Ann Oncol.
16:1401–1402. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ng AK and Mauch PM: Role of radiation
therapy in localized aggressive lymphoma. J Clin Oncol. 25:757–759.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bonnet C, Fillet G, Mounier N, et al:
Groupe d'Etude des Lymphomes de l'Adulte: CHOP alone compared with
CHOP plus radiotherapy for localized aggressive lymphoma in elderly
patients: A study by the Groupe d'Etude des Lymphomes de l'Adulte.
J Clin Oncol. 25:787–792. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Reyes F, Lepage E, Ganem G, et al: Groupe
d'Etude des Lymphomes de l'Adulte (GELA): ACVBP versus CHOP plus
radiotherapy for localized aggressive lymphoma. N Engl J Med.
352:1197–1205. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Beal K, Allen L and Yahalom J: Excellent
long-term experience with primary bone lymphoma: Analysis of
prognostic factors. J Clin Oncol. 22:65872004.
|
|
29
|
Cai L, Stauder MC, Zhang YJ, et al:
Early-stage primary bone lymphoma: a retrospective, multicenter
rare cancer network (RCN) study. Int J Radiat Oncol Biol Phys.
83:284–291. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Barbieri E, Cammelli S, Mauro F, et al:
Primary non-Hodgkin's lymphoma of the bone: treatment and analysis
of prognostic factors for Stage I and Stage II. Int J Radiat Oncol
Biol Phys. 59:760–764. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zinzani PL, Carrillo G, Ascani S, et al:
Primary bone lymphoma: experience with 52 patients. Haematologica.
88:280–285. 2003.PubMed/NCBI
|
|
32
|
Catlett JP, Williams SA, O'Connor SC,
Krishnan J and Malkovska V: Primary lymphoma of bone: an
institutional experience. Leuk Lymphoma. 49:2125–2132. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Alencar A, Pitcher D, Byrne G and Lossos
IS: Primary bone lymphoma - the university of miami experience.
Leuk Lymphoma. 51:39–49. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pellegrini C, Gandolfi L, Quirini F, et
al: Primary bone lymphoma: evaluation of chemoimmunotherapy as
front-line treatment in 21 patients. Clin Lymphoma Myeloma Leuk.
11:321–325. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Horning SJ, Weller E, Kim K, et al:
Chemotherapy with or without radiotherapy in limited-stage diffuse
aggressive non-Hodgkin's lymphoma: Eastern cooperative oncology
group study 1484. J Clin Oncol. 22:3032–3038. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Messina C, Ferreri AJ, Govi S, et al:
International Extranodal Lymphoma Study Group (I.E.L.S.G.):
Clinical features, management and prognosis of multifocal primary
bone lymphoma: a retrospective study of the international
extranodal lymphoma study group (the IELSG 14 study). Br J
Haematol. 164:834–840. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gutierrez-Garcia G, Colomo L, Villamor N,
et al: Clinico-biological characterization and outcome of primary
nodal and extranodal diffuse large B-cell lymphoma in the rituximab
era. Leuk Lymphoma. 51:1225–1232. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Rieger M, Osterborg A, Pettengell R, et
al: MabThera International Trial (MInT) Group: Primary mediastinal
B-cell lymphoma treated with CHOP-like chemotherapy with or without
rituximab: results of the Mabthera International Trial Group study.
Ann Oncol. 22:664–670. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Feugier P, Van Hoof A, Sebban C, et al:
Long-term results of the R-CHOP study in the treatment of elderly
patients with diffuse large B-cell lymphoma: a study by the Groupe
d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 23:4117–4126.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Pfreundschuh M, Trumper L, Osterborg A, et
al: MabThera International Trial Group: CHOP-like chemotherapy plus
rituximab versus CHOP-like chemotherapy alone in young patients
with good-prognosis diffuse large-B-cell lymphoma: a randomised
controlled trial by the MabThera international trial (MInT) group.
Lancet Oncol. 7:379–391. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sehn LH, Donaldson J, Chhanabhai M, et al:
Introduction of combined CHOP plus rituximab therapy dramatically
improved outcome of diffuse large B-cell lymphoma in British
Columbia. J Clin Oncol. 23:5027–5033. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Qian L, Zhang Z, Shen J and Liu Y: Primary
bone marrow B-cell non-Hodgkin's lymphoma successfully treated with
R-CHOP. West Indian Med J. 62:89–91. 2013.PubMed/NCBI
|
|
43
|
Shivakumar L and Armitage JO: Bcl-2 gene
expression as a predictor of outcome in diffuse large B-cell
lymphoma. Clin Lymphoma Myeloma. 6:455–457. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Mounier N, Briere J, Gisselbrecht C, et
al: Groupe d'Etude des Lymphomes de l'Adulte: Estimating the impact
of rituximab on bcl-2-associated resistance to CHOP in elderly
patients with diffuse large B-cell lymphoma. Haematologica.
91:715–716. 2006.PubMed/NCBI
|
|
45
|
Winter JN, Weller EA, Horning SJ, et al:
Prognostic significance of Bcl-6 protein expression in DLBCL
treated with CHOP or R-CHOP: a prospective correlative study.
Blood. 107:4207–4213. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Nyman H, Adde M, Karjalainen-Lindsberg ML,
et al: Prognostic impact of immunohistochemically defined germinal
center phenotype in diffuse large B-cell lymphoma patients treated
with immunochemotherapy. Blood. 109:4930–4935. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Rigacci L, Scoccianti G, Puccini B, et al:
Primary lymphoma of bone: single center experience. Drugs Cell Ther
Hematol. 2:147–156. 2013. View Article : Google Scholar
|
|
48
|
Ostrowski ML, Unni KK, Banks PM, et al:
Malignant lymphoma of bone. Cancer. 58:2646–2655. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Fidias P, Spiro I, Sobczak ML, et al:
Long-term results of combined modality therapy in primary bone
lymphomas. Int J Radiat Oncol Biol Phys. 45:1213–1218. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Horsman JM, Thomas J, Hough R and Hancock
BW: Primary bone lymphoma: a retrospective analysis. Int J Oncol.
28:1571–1575. 2006.PubMed/NCBI
|
|
51
|
Jawad MU, Schneiderbauer MM, Min ES, et
al: Primary lymphoma of bone in adult patients. Cancer.
116:871–879. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Stein ME, Kuten A, Gez E, et al: Primary
lymphoma of bone - a retrospective study. Experience at the
Northern Israel Oncology Center (1979–2000). Oncology. 64:322–327.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Govi S, Christie D, Messina C, et al:
International Extranodal Lymphoma Study Group (I.E.L.S.G.): The
clinical features, management and prognostic effects of
pathological fractures in a multicenter series of 373 patients with
diffuse large B-cell lymphoma of the bone. Ann Oncol. 25:176–181.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Kim SY, Shin DY, Lee SS, et al: Clinical
characteristics and outcomes of primary bone lymphoma in Korea.
Korean J Hematol. 47:213–218. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Matikas A, Briasoulis A, Tzannou I, et al:
Primary bone lymphoma: a retrospective analysis of 22 patients
treated in a single tertiary center. Acta Haematol. 130:291–296.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Maruyama D, Watanabe T, Beppu Y, et al:
Primary bone lymphoma: a new and detailed characterization of 28
patients in a single-institution study. Jpn J Clin Oncol.
37:216–223. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Liu YC, Gau JP, Yu YB, et al: Prognostic
factors and treatment efficacy in patients with primary diffuse
large B-cell lymphoma of the bone: single institute experience over
11 years. Intern Med. 53:95–101. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Marshall DT, Amdur RJ, Scarborough MT, et
al: Stage IE primary non-Hodgkin's lymphoma of bone. Clin Orthop
Relat Marshall Res. 405:216–222. 2002. View Article : Google Scholar
|
|
59
|
Christie D, Dear K, Le T, et al: Limited
chemotherapy and shrinking field radiotherapy for osteolymphoma
(primary bone lymphoma): results from the trans-Tasman Radiation
Oncology Group 99.04 and Australasian Leukaemia and Lymphoma Group
LY02 prospective trial. Int J Radiat Oncol Biol Phys. 80:1164–1170.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Lowry L, Smith P, Qian W, et al: Reduced
dose radiotherapy for local control in non-Hodgkin lymphoma: a
randomised phase III trial. Radiother Oncol. 100:86–92. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Scoccianti G, Rigacci L, Puccini B, et al:
Primary lymphoma of bone: outcome and role of surgery. Int Orthop.
37:2437–2442. 2013. View Article : Google Scholar : PubMed/NCBI
|
